Polaris Innovation Fund
Boston, Massachusetts, United StatesFounded 2017
The Polaris Innovation Fund, managed by Polaris Partners, aims to accelerate the commercial and therapeutic potential of early-stage academic research, focusing on healthcare, biopharma, and life sciences.
40% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (60% of deals). Average disclosed round size is $79.1M (across 5 rounds with reported amounts).
Portfolio
4
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Team
Portfolio Breakdown
Stage Distribution
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| SSatellite Bio | Series A | $110M | Apr 2022 |
 Delphia Therapeutics | Series A | $67M | — |
| SSatellite Bio | Growth | $110M | — |
| MMuna Therapeutics ApS | Series A | $73M | — |
| LLarkspur | Unknown | $35.5M | — |
Top Co-Investors
Polaris Partners3 shared
Catalio Capital Management2 shared
Alexandria Venture Investments1 shared
GV1 shared
Alphabet Inc.1 shared
Nextech Invest Ltd.1 shared
Lightspeed Venture Partners1 shared
Sanofi Ventures1 shared
LSP Dementia Fund1 shared
Sofinnova Partners1 shared
Novo Capital1 shared
VIB1 shared
3E Bioventures Capital1 shared
Med-Fine Capital1 shared
Takeda Ventures, Inc.1 shared
Last updated: 8 September 2026